Calcitonin Injection Market Report 2026

Calcitonin Injection Market Overview

• Calcitonin Injection market size has reached to $0.73 billion in 2025 • Expected to grow to $1.07 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Increasing Prevalence Of Osteoporosis Fueling The Growth Of The Market Due To Aging Population And Rising Fracture Risks • Market Trend: Fresenius Kabi Launches USP Synthetic Calcitonin Injection For Bone Disorders • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Calcitonin Injection Market?

Calcitonin injection is a type of medicine used to treat various bone conditions. The injection works by inhibiting bone breakdown (resorption) and promoting calcium excretion through the kidneys. Calcitonin is usually administered via subcutaneous or intramuscular injection and may be derived from salmon, which has a similar but more potent effect than human calcitonin. The main types of calcitonin injection are salmon calcitonin, human calcitonin, and synthetic calcitonin. Salmon calcitonin is a synthetic or naturally derived form of the hormone calcitonin originally isolated from salmon. These are used for various routes of administration, including intravenous (IV) injection, subcutaneous injection, and intramuscular injection, that are distributed through various distribution channels such as direct sales, online pharmacies, retail pharmacies, and healthcare institutions. The various drug classes include osteoporosis treatment, Paget's disease management, hypercalcemia control, and bone metastases therapy and are used by various end users such as hospitals, specialty clinics, geriatric care facilities, and home healthcare.

What Is The Calcitonin Injection Market Growth Forecast?

The calcitonin injection market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to geriatric population growth, injectable therapy demand, bone disease awareness, synthetic peptide development, specialty care expansion. Major trends in the forecast period include continued use in osteoporosis management, growth of injectable bone therapies, expansion of hypercalcemia treatment, focus on geriatric bone health, shift toward synthetic calcitonin.

Global Calcitonin Injection Market Segmentation

1) By Type Of Calcitonin: Salmon Calcitonin, Human Calcitonin, Synthetic Calcitonin 2) By Route Of Administration: Intravenous (IV) Injection, Subcutaneous Injection, Intramuscular Injection 3) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Healthcare Institutions 4) By Therapeutic Application: Osteoporosis Treatment, Pagets Disease Management, Hypercalcemia Control, Bone Metastases Therapy 5) By End-User: Hospitals, Specialty Clinics, Geriatric Care Facilities, Home Healthcare Subsegments: 1) By Salmon Calcitonin, Synthetic Salmon Calcitonin, Recombinant Salmon Calcitonin 2) By Human Calcitonin, Recombinant Human Calcitonin, Synthetic Human Calcitonin 3) By Synthetic Calcitonin, Peptide-Based Synthetic Calcitonin, Analog Synthetic Calcitonin

What Are The Drivers Of The Calcitonin Injection Market?

The increasing prevalence of osteoporosis is expected to propel the growth of the calcitonin injection market going forward. Osteoporosis refers to a medical condition characterized by decreased bone density and increased fracture risk, primarily affecting older adults, especially postmenopausal women. The increasing prevalence of osteoporosis is due to the aging population, as longer life expectancy leads to natural bone density loss and a higher risk of the disease. Calcitonin injection helps osteoporosis management by regulating calcium levels and slowing bone loss, making it effective for maintaining bone density. It provides targeted treatment through easy-to-administer injections, improving patient compliance and reducing fracture risks. For instance, in August 2024, according to Healthy Bones Australia, an Australia-based nonprofit organization focused on osteoporosis prevention and bone health, an estimated 6.2 million Australians aged 50 years and older, representing about 67 percent of this age group, were living with poor bone health in 2023, and around 23 percent of these individuals were affected by osteoporosis. Therefore, the increasing prevalence of osteoporosis is driving the growth of the calcitonin injection industry. The expansion of home healthcare services is expected to propel the growth of the calcitonin injection market going forward. Home healthcare services refer to medical and supportive care delivered to patients in their homes by licensed healthcare professionals. Home healthcare services are expanding due to the increasing shift of patients from hospital-based care to at-home care, as it helps reduce overall treatment costs while improving comfort and accessibility. The calcitonin injection market is witnessing increased demand as the rapid expansion of home healthcare services pushes providers to adopt injectable therapies that support at-home management of conditions such as osteoporosis and acute pain. For instance, in February 2023, according to the National Association for Home Care and Hospice, a US-based non-profit organization representing the interests of chronically ill, disabled and dying US nationals, approximately 12 million Americans receive some kind of home healthcare each year and that number is expected to continue to grow. Therefore, the expansion of home healthcare services is driving the growth for the calcitonin injection industry.

Key Players In The Global Calcitonin Injection Market

Major companies operating in the calcitonin injection market are Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Intas Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Wockhardt Limited, Accord Healthcare Ltd., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Mylan N.V., Cadila Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Bharat Parenterals Limited

Global Calcitonin Injection Market Trends and Insights

Major companies operating in the calcitonin injection market are focusing on developing innovative products, such as USP synthetic injections, to enhance treatment effectiveness and improve patient outcomes. USP Synthetic Injections are injectable medications that contain synthetically produced active ingredients that meet the strict quality, purity, strength, and identity standards set by the United States Pharmacopeia (USP). These injections are manufactured under regulated conditions to ensure they are safe and effective for therapeutic use. For instance, in February 2025, Fresenius Kabi, a Germany-based pharmaceutical company, launched calcitonin salmon injection, a USP synthetic, to treat symptomatic Paget’s disease of the bone and hypercalcemia. It is a sterile solution formulated for intramuscular or subcutaneous injection, available in a strength of 200 USP units per mL and packaged in a 2 mL multi-dose vial containing 400 USP units. It should be stored refrigerated between 2°C and 8°C. This injectable medication acts as a calcium regulator. It is indicated for the treatment of symptomatic Paget’s disease of bone when alternative treatments are unsuitable, hypercalcemia, and postmenopausal osteoporosis when other options are not appropriate.

Regional Insights

North America was the largest region in the calcitonin injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Calcitonin Injection Market?

The calcitonin injection market consists of sales of combination therapy packs, single-dose and multi-dose vials, branded formulations and generic versions of calcitonin products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Calcitonin Injection Market Report 2026?

The calcitonin injection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin injection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.